Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Bluebird Bio
Bluebird Bio
Bluebird Extends Cash Runway with $175M Financing to Support Gene Therapy Launch
BioSpace
Tue, 03/19/24 - 11:22 am
Bluebird Bio
funding
sickle cell disease
Lyfgenia
Bluebird bio inks first Medicaid coverage agreement for sickle cell gene therapy, signing on with Michigan
Fierce Pharma
Mon, 03/11/24 - 11:33 am
Bluebird Bio
Michigan
lovo-cel
Lyfgenia
Medicaid
sickle cell disease
gene therapy
Why Bluebird Bio Stock Dived Into the Red on Tuesday
Motley Fool
Tue, 03/5/24 - 10:18 pm
Bluebird Bio
Sickle Cell Gene Therapies Seen as Cost Effective Below $2M Threshold: Study
BioSpace
Tue, 01/23/24 - 11:18 am
gene therapy
sickle cell disease
drug pricing
Vertex Pharmaceuticals
Bluebird Bio
Bluebird bio's Lyfgenia launch progresses with 2nd major outcomes-based coverage deal
Fierce Pharma
Thu, 01/4/24 - 11:37 am
Bluebird Bio
Lyfgenia
sickle cell disease
gene therapy
Bluebird Looks to Raise $250M After Lukewarm Reception of SCD Gene Therapy
BioSpace
Tue, 12/19/23 - 10:21 am
Bluebird Bio
funding
Bluebird’s Newly Approved SCD Gene Therapy Faces Rough Road with Hefty Price Tag, Boxed Warning
BioSpace
Mon, 12/11/23 - 11:20 am
Bluebird Bio
sickle cell disease
Lyfgenia
gene therapy
CRISPR
FDA approves bluebird's sickle cell disease gene therapy. Can Lyfgenia overcome CRISPR's halo?
Fierce Pharma
Sun, 12/10/23 - 11:15 pm
Bluebird Bio
sickle cell disease
FDA
CRISPR
Lyfgenia
Bluebird won't play off Vertex in deciding price for its lovo-cel gene therapy, exec says
Fierce Pharma
Tue, 11/7/23 - 11:02 pm
Bluebird Bio
Vertex Pharmaceuticals
exa-cel
lovo-cel
sickle cell disease
drug pricing
Two Sickle Cell Disease Gene Therapies May Soon Be Approved By FDA
Forbes
Thu, 11/2/23 - 05:07 pm
sickle cell disease
gene therapy
lovo-cel
exa-cel
Vertex Pharmaceutical
CRISPR Therapeutics
Bluebird Bio
Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved
Reuters
Mon, 10/30/23 - 10:23 am
Bluebird Bio
priority review vouchers
sickle cell disease
gene therapy
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Mon, 10/2/23 - 12:00 pm
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Bluebird taps Lonza to boost manufacturing capacity for its gene therapies Zynteglo, Skysona
Fierce Pharma
Thu, 09/28/23 - 10:27 am
Bluebird Bio
gene therapy
Lonza
drug manufacturing
CDMOs
Bluebird’s Lovo-Cel Gene Therapy for SCD Will Not Face FDA Adcomm
BioSpace
Wed, 08/16/23 - 11:09 pm
Bluebird Bio
sickle cell disease
lovo-cel
FDA
Bluebird touts Zynteglo, Skysona launch progress as FDA decision on sickle cell therapy nears
Fierce Pharma
Tue, 08/8/23 - 11:33 am
Bluebird Bio
Zynteglo
Skysona
FDA
sickle cell disease
gene therapy
U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million
Reuters
Fri, 07/14/23 - 10:07 am
ICER
gene therapy
Vertex Pharmaceuticals
CRISPR Therapeutics
Bluebird Bio
drug pricing
sickle cell disease
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
Bluebird, playing catch-up, gets decision date for sickle cell gene therapy
BioPharma Dive
Wed, 06/21/23 - 11:49 am
Bluebird Bio
gene therapy
sickle cell disease
lovo-cel
FDA
Death triggers pause of 2seventy CAR-T cell therapy leukemia trial
Fierce Biotech
Wed, 06/14/23 - 10:18 am
2seventy bio
Bluebird Bio
CAR-T
patient death
clinical trials
AML
Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch
Forbes
Wed, 05/3/23 - 11:48 am
gene therapy
drug approvals
Biomarin
Bluebird Bio
FDA
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »